The present invention relates to a pharmaceutical dosage form which may comprise carbamoyl glycinated chitosan and particularly it relates to a pharmaceutical dosage form comprising the novel polymer in a lyophilized polymeric wafer form which shows rapid disintegration and dissolution characteristics in use.